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We thank Dr. Segura-Aguilar, Paris and Mun˜oz for their
interesting letter ‘‘The need of a new and more physio-
logical preclinical model for Parkinson’s disease’’ [1] that
as such nicely complement issues raised in our recent
review on Parkinson’s disease (PD) [2]. The letter by
Segura et al. brings forward some very important problems
in the field particularly related to the use of toxin models in
preclinical PD research and their value for our under-
standing the human disease and for the development of
better treatment strategies for PD patients. To clarify these
issues we would like to highlight the following points
further.
Despite great efforts made during the last 50 years by
many skilled and devoted scientists we still lack rational
disease-modifying treatments of (PD) [2–4]. As discussed
by Segura-Aguilar et al. [1] at least two major problems
and obstacles do exist that have hampered progress in this
field. One is the lack of understanding of the pathogenic
mechanisms underlying PD and its progression, and the
second concerns with the limitations of the current animal
models used to study PD.
Recent progress made in the field of molecular genetics
has led to the discovery of more than dozen genes regu-
lating different signaling pathways and cellular processes
responsible for the familial forms of PD [2–4]. These
insights have stimulated research and raised high expec-
tations that similar mechanisms would prevail in sporadic
PD representing the majority of PD patients. Unfortunately
the progress has so far been rather modest. Even in the case
of a-synuclein that was identified as the first PD causing
gene almost 20 years ago, we do not still know the precise
function of this protein in brain neurons. The funding for
PD research has no doubt increased in recent years, but we
think that one reason for the slow progress to unravel the
pathogenesis of PD are the still insufficient research
resources. There is a genuine concern about funding for
other brain diseases as well and research devoted to PD
makes no exception. The situation becomes more clear
when one considers how much resources have been
assigned to the study for example of AIDS and for the
development of drugs to prevent HIV replication. Even
with these significant resources we still lack effective
vaccines to HIV.
Segura-Aguilar et al. [1] correctly mention that the
current neurotoxin models have serious limitations. How-
ever, we should still remind that many drugs that efficiently
work in the symptomatic treatment of PD, such as cate-
chol-o-methyltransferase inhibitors, MAO-B inhibitors,
rasagiline, etc. have been developed using the MPTP and
6-OHDA animal models of PD [3]. We suggest that there is
another very important point that has not considered with
sufficient attention, as PD is a disease of aging people.
However, the vast majority of studies on rodent models of
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PD have not been performed with aged animals. There is
increasing evidence that fundamental differences in the
efficacy of neuronal signaling and capacity for neuropro-
tection do exist between young and aged animals [5]. It
would therefore be important to use also aged animals in
PD studies although this may raise the price tag of the
experiments. In this view the study of mechanisms of PD
will take the same path as that of other brain diseases such
as Alzheimer’s disease in which age, comorbidity, and the
interplay between genetic and environmental factors are
considered of utmost importance.
Regarding preclinical animal models for PD, experi-
ments based upon the use of mutated or over-expressed
genes causing familial forms of PD have largely resulted in
disappointing results [2, 3]. Thus studies of the mutant a-
synuclein, the LRRK2, and the DJ-1 and Parkin over-ex-
pressing mice showed little or no neurodegeneration in the
nigrostriatal system [6]. Recently, Wade-Martins and col-
leagues reported of a new mouse line for that may prove
more useful for the study PD [7]. These mice generated by
the use of bacterial artificial chromosome that express
wild-type a-synuclein from the complete human SNCA
locus, display an age-dependent loss of nigrostriatal
dopamine neurons and show motor impairments charac-
teristic of PD [7]. In addition in this mouse line the deficits
in dopaminergic transmission precedes neuronal loss as
most probably occurs in clinical PD. These mice will in the
coming years be very useful to study the mechanisms and
the role of a-synuclein in the pathogenesis of PD.
Another transgenic mouse line that is relevant for the
studies of PD has been generated by Larsson’s and Olson’s
groups [8]. They have used a reverse genetic approach and
conditionally disrupted the gene for mitochondrial tran-
scription factor A (Tfam) in dopamine neurons. The
knockout mice have reduced mtDNA expression and res-
piratory chain deficiency in midbrain DA neurons, leading
to a parkinsonism phenotype with adult onset of slowly
progressive impairment of motor function accompanied by
formation of intraneuronal inclusions and dopamine nerve
cell death [8].
Concerning the suitability of other experimental models,
there has been a recent interest in the use of proteasome
inhibitors to induce protein aggregation and degeneration of
dopaminergic neurons causing progressive parkinsonism in
mice [9, 10]. This strategy when combined with the study of
the role of autophagy in PD can give valuable insight into
specific disease processes in PD. Likewise the amino-
chrome model proposed and studied by Segura-Aguilar
et al. [1] has merits in focusing on the role of dopamine and
its metabolites in the function of degenerating dopamine
neurons. It would be important to study further the role and
the accumulation of aminochrome in the substantia nigra
in vivo as well as in human sporadic PD.
Segura-Aquilar et al. [1] also rightly point out that the
pathogenic mechanisms in PD include different cellular
processes such as dysfunction in protein degradation, for-
mation of protein aggregates, mitochondrial dysfunctions,
oxidative stress, neuroinflammation and ER stress. The
precise interplay between the different pathways are,
however, not fully understood nor do we know the
event(s) or environmental factors that can trigger the dis-
ease [2–4]. In our review we stressed the potential
importance of ER and associated pathways in the patho-
genesis of PD [2]. With regard to treatments use of
neurotropic factors has been often mentioned, but little data
is available on these, especially from patient material.
Although the first four phase 2 clinical trials with neu-
rotrophic factors GDNF and NRTN have either failed or
produced very modest results [5, 11] one should also
realize that intracranial delivery of proteins and viral vec-
tors is a completely new therapeutic avenue that by itself
has so many unknown aspects and potential hurdles. In
view of this it would be premature to conclude that neu-
rotropic factors do not work in human PD patients.
Encouraged by the good results obtained with the treat-
ments of rodent and non-human primate models of disease
with trophic factors we should rather try to understand how
to use this knowledge to improve the efficacy in the clinical
settings and in treatment of human PD patients.
Given the complex etiology of genetic and environ-
mental risk factors in PD it is possible that multiple events
may underlie the different forms of the disease. To
understand these in more detail more studies devoted to
detection of novel biomarkers using clinical material as
well as the generation of relevant preclinical models better
mimicking the human disease are required. With the
increased knowledge of the pathophysiological mecha-
nisms and of the neurotropic factors governing dopamine
neuron survival we may hopefully in the future arrive at a
rational treatment of the neurodegeneration in PD. In this
view it may in the long-run be able to treat individual
patients afflicted by PD with tailor-made therapies target-
ing the underlying cause and defect as done in personalized
medicine and as exemplified by modern treatments of
specific cancer subtypes.
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